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Consortium (ToxIC) Registry, 2010 to 2016
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Lehigh Valley Health Network, Department of Emergency and Hospital Medicine/USF Morsani College
of Medicine, Allentown, Pennsylvania; 2Lehigh Valley Health Network, Department of Emergency and
Hospital Medicine, Section of Medical Toxicology, Allentown, Pennsylvania; and 3University of Massachusetts Medical School, Department of Emergency Medicine, Division of Medical Toxicology, Worcester,
Massachusetts
TAGEDPABSTRACTTAGEDN
Purpose: Adults aged >65 years are susceptible to
intentional and unintentional poisoning, with contributing factors that include polypharmacy, comorbidity,
susceptibility to medication error, and gaps in research.
Although toxicologists are often tasked with managing
and preventing poisoning among older adults, little is
known about sex differences in these poisonings. The
aim of this study was to review sex differences in poisonings among older adults managed at the bedside by
medical toxicologists.
Methods: All case subjects aged >65 years in the
Toxicology Investigators Consortium (ToxIC) registry
between January 2010 and December 2016 were
reviewed. Data included reasons for exposure and consultation, exposure agents and routes, presenting clinical ﬁndings, and treatment provided. Cases missing
age, sex, or primary reason for toxicology consultation
data were excluded. We used x2 tests to assess differences in distribution of study variables according to participant sex.
Findings: Among 51,441 total registry cases, 542
(1.05%) were excluded because of missing data.
Among the remaining 50,899 cases, 2930 (5.8%) were
included for age >65 years; 52.3% of older adults
were female. Race was missing or unknown for 49.2%
of cases. Adverse drug reactions were more commonly
encountered in female subjects than in their male counterparts (9.6% vs 6.4%; P = 0.001). No statistically signiﬁcant sex differences were observed for total numbers

of intentional, unintentional pharmaceutical, and nonpharmaceutical exposures. The most common medications involved were cardiovascular (16.8%) and
analgesics/opioids (14.8%). Female subjects were more
likely than male subjects to be evaluated by a toxicologist for cardiovascular medications (18.7% vs 14.7%;
P = 0.004) and analgesics/opioids (17.6% vs 11.8%; P
< 0.001). Male subjects were more likely than female
subjects to be evaluated for ethanol toxicity (7.4% vs
1%; P < 0.001) and for envenomations (4.2% vs
1.8%; P < 0.001). The most common route of exposure
was oral ingestion (81.3%). Signs/symptoms were noted
in 54.8% of cases, with the most common abnormal
vital sign being bradycardia (17.2%). Pharmacologic
support was the most common intervention and was
more common in male subjects than in female subjects
(17.7% vs 12.3%; P < 0.001). Deaths were reported in
38 female subjects (2.45%) and 46 male subjects
(3.34%); there was no statistically signiﬁcant difference
in death rate according to sex (P = 0.148).
Implications: Older female adults were more commonly evaluated by a medical toxicologist for an
adverse drug reaction than older male adults. Female
patients were more likely than male patients to be
evaluated for poisoning related to analgesic/opioids and
cardiovascular medications, and older male patients
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more frequently received pharmacologic support than
older female patients. No signiﬁcant sex differences
were observed in numbers of toxicology consultations
for
intentional,
unintentional
pharmaceutical,
and nonpharmaceutical exposures. (Clin Ther.
2018;40:13661374) © 2018 Elsevier Inc. All rights
reserved.
Key words: management, medical toxicology, older
adults, prevention, poisonings, sex differences.

TAGEDH1INTRODUCTIONTAGEDN
Over the next 25 years, it is projected that the number
of people aged >65 years will increase by 27 million
per year.1 Polypharmacy is common in older individuals, which, in an aging population, will likely lead to
higher rates of pharmaceutical-related drug events.
Older adults are vulnerable to medication-related toxicity due to changes in metabolism and excretion, declining functional capacity, dosing error, polypharmacy,
and nonadherence with medications. There is an accompanying need to address these concerns with education
and prevention efforts.25 It is of great importance to
recognize sex differences related to risk factors and outcomes associated with adverse drug events.2,3,68
The increased risk of adverse drug events related to
pharmaceuticals among female patients is multifactorial; a major contributing factor is the exclusion of
female participation in clinical research and thus a subsequent lack of sex-based dosing recommendations for
speciﬁc medications.911 Most drugs that have been
withdrawn from the market in the United States posed
greater health risks for female subjects than for male
subjects.9,12 There are known pharmacokinetic and
pharmacodynamic effects from both sex- and agerelated differences, and these differences likely contribute to the increased risk of adverse drug events among
older adults, and particularly among older female
subjects.13 Physiological contributors include sex
differences in plasma volume, protein-binding, drug
metabolism, and drug receptor concentrations.11,1418
Clinical manifestations of such sex differences include
increased susceptibility to both therapeutic and adverse
effects of common medications such as zolpidem,19
morphine,10,20,21 and rocuronium.10,22 Notably,
female subjects have an increased risk for drug-induced
torsades de pointes, a lethal cardiac dysrhythmia.23,24

Sex differences in risk factors related to suicide
attempts are well established, with female subjects
exhibiting higher risks both for suicide attempt by nonviolent methods (eg, ingestion) and for suicide attempt
without completion.25,26 Functional and physical
impairments contribute to risk of suicide in adults,
with chronic pain associated with a higher risk of suicide in male subjects compared with female subjects in
the elderly population.4
It is crucial to understand sex differences in adverse
drug events and poisonings among older adults to
improve medication safety in this population. In this
sex-based analysis of the Toxicology Investigators
Consortium (ToxIC) registry, the study aim was to
describe toxicologists’ encounters in health care facilities with older adult patients. Evaluating sex-based
effects on the types of poisonings, clinical outcomes,
and the reason(s) underlying the poisonings, our goal
was to provide hypothesis-generating data that will
guide future research to inform prevention practices
and management directed at older adults.

TAGEDH1PATIENTS AND METHODSTAGEDN
Data for these analyses were queried from the ToxIC
registry. This registry, established in 2010 by the American College of Medical Toxicology, prospectively collects information reported by medical toxicologists
evaluating patients in both inpatient and outpatient settings.27 Participating toxicologists at 79 facilities in the
United States and Israel voluntarily enter de-identiﬁed
data on patients evaluated at the bedside by using an
online data collection form that is maintained by the
American College of Medical Toxicology. These data
include demographic characteristics such as race, sex,
and age; clinical presentation; setting of consultation;
interventions provided (eg, antidotes, pharmacologic
and nonpharmacologic treatments, elimination, decontamination); type of poisoning; and reason for the toxicologic exposure. The Supplemental Appendix
(provided in the online version at https://doi.org/
10.1016/j.clinthera.2018.06.012) describes the data
entry ﬁelds used in submission of the toxicology consultation cases to the ToxIC registry.
This study was evaluated and deemed exempt by the
institutional review board. Abstracted data included
patient-related variables such as sex, race, and age. The
following data were queried from the registry: data
pertaining to reasons for exposure and consultation;
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exposure agents and routes; presenting clinical ﬁndings, including toxidromes, vital sign abnormalities,
and organ effects such as cardiovascular, pulmonary,
nervous system, metabolic, gastrointestinal, hematologic, renal, muscle, and dermatologic abnormalities;
and treatment provided, including antidotes, antivenom, chelators, pharmacologic support, decontamination, elimination, and nonpharmacologic support.
Cases were excluded if there was missing information
on age, sex, or reason for toxicology consult. These
analyses included all registry cases for patients who
were categorized as aged >65 years between January
1, 2010, and December 31, 2016.
Descriptive and relative frequencies along with
graphical methods were used to evaluate the characteristics of the study population. To assess differences in
distribution of study variables according to participant
sex, x2 tests were used. Because multiple comparisons
were made within exposure types, exposure agents,
and symptoms, the a level for a statistically signiﬁcant
result was adjusted and set at 0.5% or <0.005
(a/10 = 0.005). All analyses were performed with Stata
SE version 14.2 (Stata Corp, College Station, Texas).

TAGEDH1RESULTSTAGEDN
A total of 51,441 observations were included in the
ToxIC registry during the study period. Of these, 542
(1.05%) were excluded due to missing data on age category, sex, or reason for toxicologic consult. Among
the remaining 50,899 case subjects, 2930 (5.8%) were
aged >65 years and were included in these analyses.
The table presents the characteristics of the study sample and the details of toxicology consultation according
to patient sex. A majority (52.3%; n = 1553) of the
older adults were female. Race/ethnicity was missing or
unknown for 49.2% of cases (n = 1442), but regardless
of uncertainty for a plurality of the sample, the distribution of race was similar between male subjects and
female subjects (P = 0.88).
The table shows the most frequent reason for toxicology consultation stratiﬁed according to patient sex.
Intentional pharmaceutical exposures were the most
frequent reason for the toxicology consultation overall, accounting for 34.3% (n = 1005) of all observations in the registry for this age group. There was a
nonsigniﬁcant trend toward female subjects presenting
more frequently than male subjects for intentional
pharmaceutical exposures (36.4% vs 32.0%;
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P = 0.01). No sex differences were observed for nonpharmaceutical exposures and for unintentional pharmaceutical exposures. There were no signiﬁcant
differences in the route of exposure; the vast majority
were oral ingestions (81.3%). Clinical signs/symptoms
were noted in 54.8% of cases, with bradycardia being
cited as the most common abnormal vital sign
(17.1%), with no signiﬁcant sex differences.
Adverse drug reactions were more commonly
encountered in female subjects than in their male counterparts (9.6% vs 6.4%; P = 0.001). Among adverse
drug reactions, the most common speciﬁc medications
involved were digoxin (21 female subjects, 7 male subjects), metoprolol (6 female subjects, 2 male subjects),
quetiapine (5 male subjects), and lithium (4 female subjects).
Overall, the most common classes of medications
involved in poisonings among older adults were cardiovascular (16.8%) followed by analgesics/opioids
(14.8%). Female subjects were more likely than male
subjects to be evaluated for cardiovascular medications
(18.7% of female subjects vs 14.7% of male subjects;
P = 0.004) and analgesics/opioids medications (17.6%
of female subjects vs 11.8% of male subjects; P <
0.001). Male subjects were more likely than female
subjects to be evaluated for ethanol toxicity (7.4% of
male subjects vs 1% of female subjects; P < 0.001) and
for envenomations (4.2% of male subjects vs 1.8 % of
female subjects; P < 0.001).
The most common cardiovascular medications
involved in poisonings for both male and female subjects were digoxin, beta-blockers, and calcium channel
blockers; bradycardia was the most common presenting medication effect. The most commonly reported
cardiovascular medications in female cases included
digoxin (136 cases), metoprolol (28 cases), diltiazem
(23 cases), amlodipine (17 cases), and atenolol (11
cases). Among these poisonings, there were 57 female
subjects who experienced bradycardia. The most commonly reported cardiovascular medications in male
cases included digoxin (94 cases), metoprolol (29
cases), amlodipine (16 cases), diltiazem (15 cases), and
verapamil (8 cases), resulting in 52 cases of bradycardia. The most common analgesics involved in poisonings for both male subjects and female subjects were
acetaminophen, aspirin, and ibuprofen. Acetaminophen exposures were reported in 109 female subjects
and 54 male subjects; aspirin exposures were reported
in 32 female subjects and 19 male subjects; and
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Table.

Description of patient and exposure characteristics for older adult patients from the Toxicology Investigators Consortium (ToxIC) Registry, stratiﬁed according to patient sex. Values are given as no. (%).

Variable

Coding

Overall
(n = 2930
[100.0%])

Female
Subjects
(n = 1533
[52.3%])

Male
Subjects
(n = 1397
[47.7%])

P*

Race

Asian
Black/African American
White/Caucasian
Other
Unknown/ uncertain/missing

59 (2)
223 (7.6)
1098 (37.5)
108 (3.7)
1442 (49.2)

28 (1.8)
122 (8.0)
576 (37.6)
55 (3.6)
752 (49.1)

31 (2.2)
101 (7.2)
522 (37.4)
53 (3.8)
690 (49.4)

0.88

Reason for consultation
(top 10)

Intentional pharmaceutical
Intentional nonpharmaceutical
Unintentional pharmaceutical
Adverse drug reactiony
Organ system dysfunction
Unintentional nonpharmaceutical
Interpretation of toxicology
laboratory dataz
Environmental evaluationx
Unknown
More than 1 reason

1005 (34.3)
368 (12.6)
239 (8.2)
236 (8.1)
167 (5.7)
152 (5.2)
137 (4.7)

558 (36.4)
209 (13.6)
138 (9.0)
147 (9.6)
87 (5.7)
74 (4.8)
63 (4.1)

447 (32.0)
159 (11.4)
101 (7.2)
89 (6.4)
80 (5.7)
78 (5.6)
74 (5.3)

0.01
0.07
0.08
0.001
0.95
0.36
0.13

101 (3.5)
94 (3.2)
84 (2.9)

51 (3.3)
54 (3.5)
34 (2.2)

50 (3.6)
40 (2.9)
50 (3.6)

0.71
0.31
0.03

Cardiovascular
Sedative-hypnotic/muscle relaxer
Analgesic
Opioid
Antidepressant
Alcohol ethanol
Diabetic medication
Metals
Anticonvulsant
Envenomation

493 (16.8)
242 (8.3)
233 (8)
202 (6.9)
122 (4.2)
120 (4.1)
109 (3.7)
93 (3.2)
89 (3)
85 (2.9)

287 (18.7)
142 (9.3)
153 (10.0)
117 (7.6)
78 (5.1)
16 (1.0)
56 (3.7)
40 (2.6)
45 (2.9)
27 (1.8)

206 (14.8)
100 (7.2)
80 (5.7)
85 (6.1)
44 (3.2)
104 (7.4)
53 (3.8)
53 (3.8)
44 (3.2)
58 (4.2)

0.004
0.04
<0.001
0.1
0.009
<0.001
0.84
0.07
0.74
<0.001

103 (8.6)
60 (5.0)
206 (17.1)
58 (4.8)
35 (2.9)
7 (0.6)
543 (45.2)
190 (15.8)

50 (8.0)
31 (5.0)
119 (19.0)
31 (5.0)
19 (3.0)
3 (0.5)
256 (41.0)
116 (18.6)

53 (9.2)
29 (5.0)
87 (15.1)
27 (4.7)
16 (2.8)
4 (0.7)
287 (49.7)
74 (12.8)

0.46
0.96
0.07
0.82
0.78
0.63
0.002
0.006

Agent (top 10)

Symptoms (most common) Hypotension
Hypertension
Bradycardia
Tachycardia
Bradypnea
Hyperthermia
None
Multiple symptoms

(continued)
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Table.

(Continued)
Female
Subjects
(n = 1533
[52.3%])

Male
Subjects
(n = 1397
[47.7%])

P*

Variable

Coding

Overall
(n = 2930
[100.0%])

Medical intervention

No
Yes

2257 (77.0) 1210 (78.9) 1047 (75.0) 0.01
673 (23.0) 323 (21.1) 350 (25.0)

Medical intervention type

Pharmacologic support
Intubation
Both pharmacologic support
and intubation

568 (19.4)
237 (8.1)
132 (4.5)

262 (17.1)
134 (8.7)
73 (4.8)

306 (21.9)
103 (7.4)
59 (4.2)

<0.001
0.18
0.48

Pharmacologic
support (top 5)

Benzodiazepines
Vasopressors
Multiple treatments
Glucose
Opioids

241 (8.2)
130 (4.4)
76 (2.6)
60 (2.1)
31 (1.1)

101 (6.6)
73 (4.8)
37 (2.4)
24 (1.6)
12 (0.8)

140 (10.0)
57 (4.1)
39 (2.8)
36 (2.6)
19 (1.4)

0.001
0.37
0.52
0.05
0.13

* Results should be considered statistically different for exposure, agent type, and symptoms if P values are <0.005.
y Deﬁned as poisoning occurring at therapeutic dosing.
z Deﬁned as consult to assist with clinical signiﬁcance of results such as drug testing.
x Deﬁned as consult regarding potential exposure to toxicity from the environment (ie, workplace or home).

ibuprofen exposures were reported in 7 female subjects
and 2 male subjects.
Although there was a nonsigniﬁcant trend toward
medical interventions being more common in male subjects (25.1% vs 21.1%; P = 0.01), pharmacologic support was used more commonly among male subjects
(17.7% of male subjects vs 12.3% of female subjects; P
< 0.001). Deaths were reported in 38 female (2.45%)
and 46 male (3.34%) patients, with no statistically signiﬁcant difference in death rate according to sex
(P = 0.148).

TAGEDH1DISCUSSIONTAGEDN
Among patients included in the ToxIC registry, female
encounters were more frequent than male encounters,
and the most common reason for bedside toxicology
consultation for older adults was intentional overdose.
Although this study did not report a statistically signiﬁcant difference between sexes in intentional overdose,
given an aging population, this study raises concerns
that older adults are vulnerable to poisoning by
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intentional ingestion. The available literature shows
that female patients are more likely than male subjects
to attempt suicide by pharmaceutical overdose,
whereas male subjects are more likely to complete suicide by violent means.26 These data are consistent with
both the known increased rate of adverse outcomes
related to drugs among female subjects9,12 and the
more frequent use of pharmaceuticals in female subjects in a suicide attempt.
The World Health Organization deﬁnes an adverse
drug reaction as a “response to a drug which is noxious
and unintended, and which occurs at doses normally
used for the prophylaxis, diagnosis, or therapy of disease or for the modiﬁcations of physiological function.”28 Among older adults, female subjects are
particularly susceptible to adverse drug reactions given
the known sex differences in pharmacokinetic and
pharmacodynamic processes that determine both therapeutic and adverse responses to medications.14,16,29,30
The present study found a female predominance
among exposures to cardiovascular medications and
analgesic medications, both of which are classes of
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drugs with the potential for severe toxicity in poisoning.31,32 Speciﬁcally, calcium channel blockers, betablockers, and digoxin were the cardiovascular agents
most commonly associated with poisoning among
both male and female older adults. This ﬁnding is of
particular importance because it may inform future
research geared toward education and prevention
efforts by providers caring for patients at risk for poisoning. Given that there is clinical evidence to support
sex and gender differences in multiple aspects of cardiovascular disease, including how patients are managed and response to therapies,33 the results of this
study further support the need to explore how patients
vary according to sex and gender in both therapeutic
and supratherapeutic effects of cardiovascular medications.
It is not surprising that older female adults were evaluated more often for poisoning due to analgesics. The
available literature supports that female subjects more
frequently report pain, more commonly experience painful conditions, and experience more side effects from
medications used to treat pain.3440 Of particular concern was that both older male and female adults were
affected by poisonings due to aspirin and acetaminophen, both of which can cause signiﬁcant toxicity.41
The increased prevalence of poisoning due to ethanol in older male adults in this study is consistent with
the known increased risk among male subjects for alcohol-related morbidity and mortality.42 The ﬁnding that
ethanol was the sixth most common source of poisoning among older adults indicates the need for further
research geared toward prevention, with a particular
emphasis on at-risk male patients. Envenomations
among older male subjects were more than double
those among older female subjects in this study, which
is consistent with the known increased risk of envenomations among male subjects.43
Intentional nonpharmaceutical ingestions, which
include both self-harm and misuse/abuse ingestions,
were reported in both male and female older adults in
this study. Psychiatric illness along with substance use
disorder are the most common risk factors for suicide in
older adults, and rates of substance use disorder in people aged >50 years are expected to increase by 2.9 million by 2020.4,5 Given this growing risk of substance
use disorders among older adults, prevention efforts
geared toward this age group are essential, and more
research is needed on how to best target these
approaches in a sex-speciﬁc manner.5 Sex-based

assessments for substance use, as well as underlying psychiatric comorbidity, may be important in terms of poisoning prevention efforts. Continued research needs to
be conducted on types of medications and ingestions in
older adults so that prevention of suicide can be directed
toward speciﬁc agents.4 Although all older adults merit
screening for risk factors for self-harm attempts, a sexbased approach remains warranted given the existing literature on sex differences in suicides and that this study
showed that female subjects may be at increased risk for
poisoning by medications such as cardiovascular and
analgesic medications, which can be particularly deadly
in overdose.
Unintentional pharmaceutical poisonings as well as
adverse drug reactions represent an opportunity to
consider the dangers of polypharmacy within this vulnerable population.8 Even in the absence of risk factors for self-harm attempts, older adults with
polypharmacy remain at risk for poisoning due to
unintentional poisoning. Clinicians prescribing medications to older adults must be cognizant of the risks
of prescribing multiple medications. Medication
review, medication reconciliation, and bedside education surrounding appropriate medication use, storage,
and disposal should also be performed. Reducing
unnecessary prescribing, assessing for medication
compliance, and addressing unsafe co-prescribing
may reduce risk factors for adverse drug events.3
Although all older adults remain at risk for adverse
drug outcomes,3,8 clinicians screening patients for
risk factors for such outcomes, including polypharmacy, and cognitive decline as a contributor to dosing
errors should be particularly aware of the increased
risk among female patients.
One limitation of the present study is that the data
were drawn from a registry that relies on toxicologists
voluntarily reporting to the database and correctly
identifying the underlying cause of a poisoning. It is
likely that the registry consists of a selection of higher
acuity poisonings for which a toxicologist was consulted, and these data may therefore represent poisonings with increased severity compared with the general
population of older adults presenting to hospitals with
poisoning. Furthermore, the data are limited by the
potential for missing cases (ie, those seen by toxicologists but not entered into the registry), as well as missing or incorrect data points for reported cases, which
represent potential but not conﬁrmed poisonings.
Finally, beyond sex-related effects, there may be
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variables that place a patient at risk for poisoning that
were not available for analysis in this study.

TAGEDH1SUPPLEMENTARY MATERIALTAGEDN
Supplementary data associated with this article can be
found in the online version at https://doi.org/10.1016/
j.clinthera.2018.06.012.

TAGEDH1CONCLUSIONSTAGEDN

In a dataset of cases of adults aged >65 years evaluated
at the bedside by a medical toxicologist, adverse drug
reactions were more common in older female subjects
than in older male subjects. Female patients were more
frequently evaluated and managed by a toxicologist for
poisoning by cardiovascular and analgesic medications, whereas male patients were more commonly
managed for ethanol toxicity and envenomation. Older
male subjects treated for poisoning more frequently
were recipients of pharmacologic support. No signiﬁcant sex differences were observed for intentional
exposures, unintentional pharmaceutical exposures,
and nonpharmaceutical exposures. Further study into
sex variables in all types of poisonings among older
adults could improve care of poisoned patients as well
as approaches to poisoning prevention.
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